The identification of AP-1 TF network as the central hub in the early T. cruzi induced fibrotic response makes it an attractive starting point for the development of small molecule inhibitors for the management of downstream T. cruzi induced cardiomyopathy. Here, TF is linked to cardiomyopathy.